hydroxyurea has been researched along with Central Nervous System Neoplasm in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs." | 2.73 | Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. ( Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desjardins, A | 1 |
| Quinn, JA | 1 |
| Vredenburgh, JJ | 1 |
| Sathornsumetee, S | 1 |
| Friedman, AH | 1 |
| Herndon, JE | 1 |
| McLendon, RE | 1 |
| Provenzale, JM | 1 |
| Rich, JN | 1 |
| Sampson, JH | 1 |
| Gururangan, S | 1 |
| Dowell, JM | 1 |
| Salvado, A | 1 |
| Friedman, HS | 1 |
| Reardon, DA | 1 |
| Chamberlain, MC | 1 |
| Levin, VA | 1 |
1 trial available for hydroxyurea and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamide | 2007 |
1 other study available for hydroxyurea and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Primary central nervous system lymphoma: a role for adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1992 |